ArticleCancer medicine2022
Clinical significance of 206 station lymph node in transverse colon cancer.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Clinicopathologic and prognostic factors of patients with T3/T4 colorectal signet ring cell carcinoma: a population-based study.Journal of cancer research and clinical oncology · 2023Article
- Clinical significance of 206 station lymph node in transverse colon cancer.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymph node (LN) metastasis is crucial in determining the prognosis and treatment options for colon cancer patients. Our work was to study whether the lymph nodes beyond D3 station in transverse colon cancer, especially 206 LN, should be dissected.
methodsA total of 225 patients within our department were reviewed. The primary and secondary endpoints were overall survival (OS) and disease-free survival (DFS). We employed Propensity score weighting (PSW) for weighing participants to balance observed confounders between the 206
resultsThe rate of metastasis in station 206 was 9.3%. Only T stage (OR, 3.009; 95% CI, 1.018-8.892), N stage (OR, 9.818; 95% CI, 1.158-83.227), and M stage (OR, 26.126; 95% CI, 1.274-535.945) were an independent risk factor for 206 station metastasis in multivariate logistic analysis. The 206
conclusionStation 206 LN positive is a predictive factor for DFS. Only the patient with T1-3, N+ who is at a high risk of 206 station LN metastases should consider dissecting 206 station LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.